Louis Edouard, Bossuyt Peter, Colard Arnaud, Nakad Antoine, Baert Didier, Mana Fazia, Caenepeel Philip, Branden Stijn Vanden, Vermeire Severine, D'Heygere Francois, Strubbe Beatrijs, Cremer Anneline, Setakhr Vida, Baert Filip, Vijverman Anne, Coenegrachts Jean-Louis, Flamme Frederic, Hantson Anke, Zhou Jie, Van Gassen Geert
Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium.
Imelda GI Clinical Research Center, Imelda General Hospital, Bonheiden, Belgium.
Dig Liver Dis. 2025 Mar;57(3):707-715. doi: 10.1016/j.dld.2024.12.011. Epub 2025 Jan 8.
Fatigue is common among patients with inflammatory bowel diseases (IBDs) and is associated with decreased quality of life (QoL).
Describe fatigue evolution and identify factors associated with fatigue outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) initiating biologic treatment.
Data from adult Belgian patients with UC or CD enrolled in a prospective real-world study were utilized. Fatigue and QoL were assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and the Short Inflammatory Bowel Disease Questionnaire, respectively. Factors associated with fatigue outcomes were assessed using multivariate regression.
465 patients were included: 174 with UC and 291 with CD. Average FACIT-F scores indicated improvements in fatigue after 6 months, before stabilizing. A higher probability of fatigue disappearance was associated with clinical remission and was more likely in patients with UC than CD. Patients achieving clinical remission had lower probability of fatigue. Patients with fatigue improvements experienced greater QoL improvements than patients with fatigue persistence.
Real-world findings suggest fatigue partly improves in the first 6 months of biologic treatment. Clinical remission was associated with greater probability of fatigue disappearance and lower likelihood of fatigue persistence. Further research into factors associated with fatigue in patients with IBD is warranted.
疲劳在炎症性肠病（IBD）患者中很常见，且与生活质量（QoL）下降相关。
描述溃疡性结肠炎（UC）或克罗恩病（CD）患者开始生物治疗时疲劳的演变情况，并确定与疲劳结局相关的因素。
利用来自参加一项前瞻性真实世界研究的成年比利时UC或CD患者的数据。分别使用慢性病治疗功能评估-疲劳量表（FACIT-F）和简短炎症性肠病问卷评估疲劳和生活质量。使用多因素回归评估与疲劳结局相关的因素。
共纳入465例患者：174例UC患者和291例CD患者。FACIT-F平均得分表明，疲劳在6个月后有所改善，随后趋于稳定。疲劳消失的可能性更高与临床缓解相关，且UC患者比CD患者更有可能出现这种情况。实现临床缓解的患者疲劳的可能性更低。疲劳得到改善的患者比疲劳持续的患者生活质量改善更大。
真实世界的研究结果表明，生物治疗的前6个月疲劳部分改善。临床缓解与疲劳消失的可能性更大和疲劳持续的可能性更低相关。有必要进一步研究IBD患者疲劳的相关因素。
